Ilya Pharma will present poster of non-clinical data of ILP100-Oral at IBD Nordic Conference November 27-29, Malmö
Abstract: Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models
Presenter: Dr Yanhong Pang
Full program: https://ibdnordic.se/wp-content/uploads/2024/11/IBD-program_2024_till-hemsidan-1.pdf
Conference Scientific Committee: https://ibdnordic.se/scientific-committee/